Company intelligence / Profile preview
Angel Pharmaceuticals
Jiaxing, Zhejiang, Chinaangelpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
CPI-818 (soquelitinib) has been approved by the FDA to enter Phase 3 clinical trials for relapsed/refractory peripheral T cell lymphoma. Preliminary results have shown tumor responses in advanced, refractory T cell malignancies. CPI-006 (mupadolimab) is in clinical trials for non-small cell lung cancer and has shown impressive efficacy data. ANG-0623 has obtained Phase 1 clinical trial approvals from the U.S. FDA and China CDE for multiple sclerosis treatment[1][5][9].
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Small moleculesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Corvus Pharmaceuticals, Inc. (strategic collaboration)
Beyond the preview
Go deeper on Angel Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angel Pharmaceuticals.